Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-26T21:02:05.391Z Has data issue: false hasContentIssue false
  • English
  • Français

Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies

Published online by Cambridge University Press:  23 May 2008

Constantine G. Lyketsos ,
Christine A. Szekely ,
Michelle M. Mielke ,
Paul B. Rosenberg  and
Peter P. Zandi
Constantine G. Lyketsos*
Affiliation:
Johns Hopkins Bayview, Department of Psychiatry and Behavioral Sciences, School of Medicine, and Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, U.S.A.
Christine A. Szekely
Affiliation:
Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University and Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, U.S.A.
Michelle M. Mielke
Affiliation:
Department of Psychiatry, Johns Hopkins Bayview and Johns Hopkins University, Baltimore, Maryland, U.S.A.
Paul B. Rosenberg
Affiliation:
Department of Psychiatry, Johns Hopkins Bayview and Johns Hopkins University, Baltimore, Maryland, U.S.A.
Peter P. Zandi
Affiliation:
Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, U.S.A.
*
Correspondence should be addressed to: Constantine G. Lyketsos, MD, MHS, The Elizabeth Plank Althouse Professor, Chair, Department of Psychiatry, Johns Hopkins Bayview, 5300 Alpha Commons Drive, 4th floor, Baltimore, Maryland, 21224, U.S.A. Phone: +1 410 550 0062; Fax: +1 410 550 1407. Email: kostas@jhmi.edu.
Get access

Abstract

This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.

Type
Review Article
Information
International Psychogeriatrics , Volume 20 , Issue 5 , October 2008 , pp. 871 - 889
Copyright
Copyright © International Psychogeriatric Association 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akiyama, H. et al. (2000). Inflammation and Alzheimer's disease. Neurobiology of Aging, 21, 383–421.CrossRefGoogle ScholarPubMed
Alberts, M. J. et al. (1995). ApoE genotype and survival from intracerebral haemorrhage. Lancet, 346, 575.CrossRefGoogle ScholarPubMed
Banati, R. B. (2003). Neuropathological imaging: in vivo detection of glial activation as a measure of disease and adaptive change in the brain. British Medical Bulletin, 65, 121–131.CrossRefGoogle ScholarPubMed
Bard, F. et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine, 6, 916–919.CrossRefGoogle Scholar
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A. and Wilson, R. S. (2005). Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology, 64, 834–841.CrossRefGoogle ScholarPubMed
Black, S. E. et al. (2005). A placebo-controlled, double-blind trial of the selective Abeta42-lowering agent Flurizan in patients with mild to moderate Alzheimer's disease: efficacy, safety, and follow-on results. Program No. 585.6. Society for Neuroscience Abstracts.Google Scholar
Blacker, D. et al. (1997). ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology, 48, 139–147.CrossRefGoogle ScholarPubMed
Brookmeyer, R. and Gray, S. (2000). Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease. Statistics in Medicine, 19, 1481–1493.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
Brookmeyer, R., Gray, S. and Kawas, C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health, 88, 1337–1342.CrossRefGoogle ScholarPubMed
Brookmeyer, R., Corrada, M. M., Curriero, F. C. and Kawas, C. (2002). Survival following a diagnosis of Alzheimer disease. Archives of Neurology, 59, 1764–1767.CrossRefGoogle ScholarPubMed
Cagnin, A. et al. (2001). In-vivo measurement of activated microglia in dementia. Lancet, 358, 461–467.CrossRefGoogle ScholarPubMed
Carroll, K. A. L., Rosenberg, P. B., Lyketsos, C. and Kaplin, A. (2007). IL-6 Release by Peripheral Blood Mononuclear Cells as a Potential Biomarker for Alzheimer's Disease. Paper presented at the American Association of Geriatric Psychiatry annual meeting, New Orleans LA.Google Scholar
Caselli, R. J. et al. (2004). Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology, 62, 1990–1995.CrossRefGoogle ScholarPubMed
Crowe, M., Andel, R., Pedersen, N. L., Johansson, B. and Gatz, M. (2003). Does participation in leisure activities lead to reduced risk of Alzheimer's disease? A prospective study of Swedish twins. Journal of Gerontology Series B, Psychological Sciences and Social Sciences, 58, 249–255.CrossRefGoogle ScholarPubMed
de Leon, M. J. et al. (2004). MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine, 256, 205–223.CrossRefGoogle ScholarPubMed
de Leon, M. J. et al. (2006). Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiology of Aging, 27, 394–401.CrossRefGoogle ScholarPubMed
Eikelenboom, P. and Van Gool, W. A. (2004). Neuroinflammatory perspectives on the two faces of Alzheimer's disease. Journal of Neural Transmission, 111, 281–294.CrossRefGoogle ScholarPubMed
Eriksen, J. L. et al. (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. Journal of Clinical Investigation, 112, 440–449.CrossRefGoogle ScholarPubMed
Evans, D. A. et al. (1997)). Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Archives of Neurology, 54, 1399–1405.CrossRefGoogle Scholar
Ferri, C. P. et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 2112–2117.CrossRefGoogle ScholarPubMed
Fitzpatrick, A. L., Kuller, L. H., Lopez, O. L., Kawas, C. H. and Jagust, W. (2005). Survival following dementia onset: Alzheimer's disease and vascular dementia. Journal of Neurological Science, 229–230, 43–49.CrossRefGoogle Scholar
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.CrossRefGoogle ScholarPubMed
Fox, N. C. et al. (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 64, 1563–1572.CrossRefGoogle ScholarPubMed
Fritsch, T., Smyth, K. A., Debanne, S. M., Petot, G. J. and Friedland, R. P. (2005). Participation in novelty-seeking leisure activities and Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology, 18, 134–141.CrossRefGoogle ScholarPubMed
Gao, S., Hendrie, H. C., Hall, K. S. and Hui, S. (1998). The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Archives of General Psychiatry, 55, 809–815.CrossRefGoogle ScholarPubMed
Gauthier, S. et al. (2006). Mild cognitive impairment. Lancet, 367, 1262–1270.CrossRefGoogle ScholarPubMed
Gilman, S. et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553–1562.CrossRefGoogle Scholar
Gitter, B. D. et al. (2004)). Stereoselective inhibition of amyloid beta peptide secretion by LY450139 dihydrate, a novel functional gamma secretase inhibitor. Neurobiology of Aging, 25, S571.CrossRefGoogle Scholar
Gleason, C. E. et al. (2001). Effects of raloxifene on verbal memory in women with Alzheimer's disease. Program No. 546.17. Society for Neuroscience Abstracts.Google Scholar
Green, R. C. et al. (2003). Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Archives of Neurology, 60, 753–759.CrossRefGoogle ScholarPubMed
Hendrie, H. C. (1998). Epidemiology of dementia and Alzheimer's disease. American Journal of Geriatric Psychiatry, 6, S3–18.CrossRefGoogle ScholarPubMed
Honig, L. S. et al. (2003). Stroke and the risk of Alzheimer disease. Archives of Neurology, 60, 1707–1712.CrossRefGoogle ScholarPubMed
Horsburgh, K., McCarron, M. O., White, F. and Nicoll, J. A. (2000). The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiology of Aging, 21, 245–255.CrossRefGoogle ScholarPubMed
in ‘t Veld, B. A. et al. (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. New England Journal of Medicine, 345, 1515–21.CrossRefGoogle ScholarPubMed
JackC. R., Jr. C. R., Jr. et al. (2003). MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology, 60, 253–260.CrossRefGoogle Scholar
Karp, A., Kareholt, I., Qiu, C., Bellander, T., Winblad, B. and Fratiglioni, L. (2004). Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. American Journal of Epidemiology, 159, 175–183.CrossRefGoogle ScholarPubMed
Khachaturian, A. S., Corcoran, C. D., Mayer, L. S., Zandi, P. P. and Breitner, J. C. (2004). Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Archives of General Psychiatry, 61, 518–524.CrossRefGoogle Scholar
Klunk, W. E. et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306–319.CrossRefGoogle ScholarPubMed
Leoni, V., Masterman, T., Patel, P., Meaney, S., Diczfalusy, U. and Bjorkhem, I. (2003). Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. Journal of Lipid Research, 44, 793–799.CrossRefGoogle ScholarPubMed
Luchsinger, J. A. and Mayeux, R. (2004). Cardiovascular risk factors and Alzheimer's disease. Current Atherosclerosis Reports, 6, 261–266.CrossRefGoogle ScholarPubMed
Lutjohann, D. and von Bergmann, K. (2003). 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry, 36 (Suppl.2), S102–S106.Google ScholarPubMed
Lyketsos, C. G. et al. . (2006). Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia due to Alzheimer's disease. American Journal of Geriatric Psychiatry, 14, 561–572.CrossRefGoogle Scholar
May, P. C., Yang, Z., Li, W., Hyslop, P. A., Siemers, E. R. and Boggs, L. N. (2004). Multi-compartmental pharmaco-dynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiology of Aging, 25, S65.CrossRefGoogle Scholar
McGeer, E. G. and McGeer, P. L. (2003). Inflammatory processes in Alzheimer's disease. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 741–749.CrossRefGoogle ScholarPubMed
Meyer, M. R. et al. (1998). APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer disease. Nature Genetics, 19, 321–322.CrossRefGoogle Scholar
Mielke, M. M. et al. (2006). Low serum potassium in mid life associated with decreased cerebrospinal fluid Abeta42 in late life. Alzheimer Disease and Associated Disorders, 20, 30–36.CrossRefGoogle ScholarPubMed
Mielke, M. M., Haughy, N., Bandaru, V. V. R., Carlson, M. C., Rabins, P. V. and Lyketsos, C. (2007a). Development of blood-based lipid biomarkers for Alzheimer's disease prevention. Paper presented at the American Association for Geriatric Psychiatry annual meeting, New Orleans LA.Google Scholar
Mielke, M. M., Haughy, N., Bandaru, V. V. R., Rabins, P. V., Lyketsos, C. G. and Carlson, M. C. (2007b). Serum sphingomyelins and ceramides predict development of memory impairment in a population-based longitudinal study. Paper presented at the International College of Geriatric Psychoneuropharmacology (ICGP) conference, San Diego CA.Google Scholar
Mielke, M. M. et al. (2007c). Vascular factors predict rate of progression in Alzheimer disease. Neurology, 69, 1850–1858.CrossRefGoogle Scholar
Mielke, M. M. et al. (2008). Regionally specific diffusion tensor imaging measures in Alzheimer's disease, MCI, and controls. Paper presented at the International Conference on Prevention of Dementia, Washington DC.Google Scholar
Montine, T. J., Montine, K. S., McMahan, W., Markesbery, W. R., Quinn, J. F. and Morrow, J. D. (2005). F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxidants and Redox Signaling, 7, 269–275.CrossRefGoogle ScholarPubMed
Moreira, P. I. et al. (2005). Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Current Alzheimer Research, 2, 403–408.CrossRefGoogle ScholarPubMed
Morris, M. C. et al. (2002). Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA, 287, 3230–3237.CrossRefGoogle Scholar
Mortimer, J. A., Borenstein, A. R., Gosche, K. M. and Snowdon, D. A. (2005). Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. Journal of Geriatric Psychiatry and Neurology, 18, 218–223.CrossRefGoogle ScholarPubMed
Nakada, T., Matsuzawa, H., Igarashi, H., Fujii, Y. and Kwee, I. L. (2008). In vivo visualization of senile plaque like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. Journal of Neuroimaging, doi:10.1111/j.1552-6569.2007.00179.x.CrossRefGoogle Scholar
Nemetz, P. N. et al. (1999). Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. American Journal of Epidemiology, 149, 32–40.CrossRefGoogle ScholarPubMed
NIH Office of Science Policy Analysis (2006). Alzheimer's Disease and Other Dementias: Summary of Methods and Data for Estimates of Costs of Illness. Accessed at http://ospp.od.nih.gov/pdf/alzheimers.pdf. Last accessed 17 July 2006.Google Scholar
Orgogozo, J. M. et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61, 46–54.CrossRefGoogle Scholar
Panza, F. et al. (2004). Mediterranean diet and cognitive decline. Public Health Nutrition, 7, 959–963.CrossRefGoogle ScholarPubMed
Petersen, R. C. et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352, 2379–2388.CrossRefGoogle ScholarPubMed
Petersen, R. C. et al. (2006). Neuropathologic features of amnestic mild cognitive impairment. Archives of Neurology, 63, 665–672.CrossRefGoogle ScholarPubMed
Podewils, L. J. et al. (2005). Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. American Journal of Epidemiology, 161, 639–651.CrossRefGoogle ScholarPubMed
Pratico, D. et al. (1998). IPF2alpha-I: an index of lipid peroxidation in humans. Proceedings of the National Academy of Sciences of the United States of America, 95, 3449–3454.CrossRefGoogle ScholarPubMed
Price, D. L. and Sisodia, S. S. (1994). Cellular and molecular biology of Alzheimer's disease and animal models. Annual Review of Medicine, 45, 435–446.CrossRefGoogle ScholarPubMed
Price, J. C. et al. (2005). Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism, 25, 1528–1547.CrossRefGoogle ScholarPubMed
Profenno, L. A., Jakimovich, L., Holt, C. J., Porsteinsson, A. and Tariot, P. N. (2005). A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. Current Alzheimer Research, 2, 553–558.CrossRefGoogle ScholarPubMed
Rabins, P. V., Lyketsos, C. G. and Steele, C. D. (2006). Practical Dementia Care. New York: Oxford Press.CrossRefGoogle Scholar
Reiman, E. M. et al. (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. New England Journal of Medicine, 334, 752–758.CrossRefGoogle ScholarPubMed
Rogers, J. et al. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609–1611.CrossRefGoogle ScholarPubMed
Rosen, W. G., Mohs, R. C. and Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356–1364.Google ScholarPubMed
Rosenberg, P. B. (2005a). Clinical aspects of inflammation in Alzheimer's disease. International Review of Psychiatry, 17, 503–514.CrossRefGoogle Scholar
Rosenberg, R. N. (2005b). Translational research on the way to effective therapy for Alzheimer disease. Archives of General Psychiatry, 62, 1186–1192.CrossRefGoogle ScholarPubMed
Rosenberg, R. N. (2006). Time will be of the essence in treating Alzheimer disease. JAMA, 296, 327–329.CrossRefGoogle Scholar
Rosenberg, P. B. (2007). Inflammatory biomarkers for treatment development in Alzheimer's disease. Paper presented at American College of Neuropsychopharmacology annual meeting, Boca Raton, FL.Google Scholar
Rosenberg, P. B., Mielke, M. M., Xue, Q. L. and Carlson, M. C. (2007). Depression and MCI in WHAS-II. Paper presented at the International Conference on Prevention of Dementia, Washington DC.Google Scholar
Rovio, S. et al. (2005). Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurology, 4, 705–711.CrossRefGoogle ScholarPubMed
Sano, M. et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine, 336, 1216–1222.CrossRefGoogle ScholarPubMed
Sastre, M., Klockgether, T. and Heneka, M. T. (2006). Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. International Journal of Developmental Neuroscience, 24, 167–176.CrossRefGoogle ScholarPubMed
Scarmeas, N., Stern, Y., Tang, M. X., Mayeux, R. and Luchsinger, J. A. (2006). Mediterranean diet and risk for Alzheimer's disease. Annals of Neurology, 59, 912–921.CrossRefGoogle ScholarPubMed
Schenk, D. et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–177.CrossRefGoogle ScholarPubMed
Schofield, P. W. et al. (1997). Alzheimer's disease after remote head injury: an incidence study. Journal of Neurology, Neurosurgery, and Psychiatry, 62, 119–124.CrossRefGoogle ScholarPubMed
Schulte, P. A. (2005). The use of biomarkers in surveillance, medical screening, and intervention. Mutation Research, 592, 155–163.CrossRefGoogle ScholarPubMed
Selkoe, D. J. (1996). Amyloid beta-protein and the genetics of Alzheimer's disease. The Journal of Biological Chemistry, 271, 18295–18298.CrossRefGoogle ScholarPubMed
Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews, 81, 741–766.CrossRefGoogle ScholarPubMed
Selkoe, D. J. (2004). Alzheimer disease: mechanistic understanding predicts novel therapies. Annals of Internal Medicine, 140, 627–638.CrossRefGoogle ScholarPubMed
Shumaker, S. A. et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 289, 2651–2662.CrossRefGoogle ScholarPubMed
Snowdon, D. A., Kemper, S. J., Mortimer, J. A., Greiner, L. H., Wekstein, D. R. and Markesbery, W. R. (1996). Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA, 275, 528–532.CrossRefGoogle ScholarPubMed
Sparks, D. L. et al. (2005). Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Archives of Neurology, 62, 753–757.CrossRefGoogle ScholarPubMed
Stewart, W. F., Kawas, C., Corrada, M. and Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48, 626–32.CrossRefGoogle ScholarPubMed
Sullivan, E. V. and Pfefferbaum, A. (2003). Diffusion tensor imaging in normal aging and neuropsychiatric disorders. European Journal of Radiology, 45, 244–255.CrossRefGoogle ScholarPubMed
Szekely, C. A. et al. (2004). Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology, 23, 159–169.CrossRefGoogle ScholarPubMed
Teasdale, G. M., Nicoll, J. A., Murray, G. and Fiddes, M. (1997). Association of apolipoprotein E polymorphism with outcome after head injury. Lancet, 350, 1069–1071.CrossRefGoogle ScholarPubMed
Watson, G. S. and Craft, S. (2003). The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs, 17, 27–45.CrossRefGoogle ScholarPubMed
Wilson, R. S. et al. (2002). Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287, 742–748.CrossRefGoogle ScholarPubMed
Wilson, R. S., Arnold, S. E., Schneider, J. A., Kelly, J. F., Tang, Y. and Bennett, D. A. (2006). Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology, 27, 143–153.CrossRefGoogle ScholarPubMed
Wyss-Coray, T. and Mucke, L. (2002). Inflammation in neurodegenerative disease–a double-edged sword. Neuron, 35, 419–432.CrossRefGoogle ScholarPubMed
Yaffe, K. et al. (2004). The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA, 292, 2237–2242.CrossRefGoogle ScholarPubMed
Yaffe, K. et al. (2005). Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. American Journal of Psychiatry, 162, 683–690.CrossRefGoogle ScholarPubMed
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L. and Breitner, J. C. (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology, 59, 880–886.CrossRefGoogle Scholar
Zandi, P. P. et al. (2004). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Archives of Neurology, 61, 82–88.CrossRefGoogle ScholarPubMed
Zarit, S. H., Reever, K. E. and Bach-Peterson, J. (1980). Relatives of the impaired elderly: correlates of feelings of burden. The Gerontologist, 20, 649–655.CrossRefGoogle ScholarPubMed
Zhang, Y. et al. (2007). Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology, 68, 13–19.CrossRefGoogle ScholarPubMed